Figure legends
Figure 1. The function of Remdesivir in the treatment of COVID-19 patients. The SARS-CoV-2 virus can enter host cells and activate the immune system through ACE2 and TMPRSS2 receptors. In patients with COVID-19, after entering the body, the virus translates its genome through the ribosome and produces RdRp. After administration, remdesivir (GS-5734) is activated, forming GS-441524, which in turn binds to RdRp and prevents virus RNA replication. Abbreviation:ACE2, Angiotensin-converting enzyme 2; TMPRSS2, Transmembrane Serine Protease 2; RdRp, RNA-dependent RNA polymerase.